Business
Willow Biosciences Announces Completion of its First Commercial Scale Fermentation Run
Willow Biosciences Announces Completion of its First Commercial Scale Fermentation Run ...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n \n \n \n Willow Biosciences Announces Completion of its First Commercial Scale Fermentation Run\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n VANCOUVER, BC,\n \n March 31, 2021\n \n /CNW/ - Willow Biosciences Inc. (\"\n \n Willow\n \n \" or the \"\n \n Company\n \n \") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it has completed the first commercial scale fermentation run of its first cannabinoid for market, cannabigerol (\"\n \n CBG\n \n \").\n \n \n \n \n \n \n \n \n \n \"We are very pleased with the yield and quality of our first commercial scale fermentation run of CBG,\" said\n \n Trevor Peters\n \n , Willow's President and Chief Executive Officer. \"I think it is important to take a moment to reflect on all that we have achieved in just under two years as a public company. In this time, we built a world class industrial R&D team, demonstrated proof of concept for production of cannabinoids through fermentation, attracted reputable development partners like Albany Molecular Research, Inc., and produced our first commercial scale batch of CBG. On the capital markets side, we have completed three successful financings bringing in supportive and sophisticated shareholders who have provided us with a healthy balance sheet to execute on our business plan. We are now starting the next phase of Willow's lifecycle, which will involve supplying commercial quantities of cannabinoids to customers and recognizing revenue therefrom.\"\n \n \n In\n \n December 2020\n \n the Company announced that it had selected a highly regarded contract manufacturing organization (\"\n \n CMO\n \n \") to commercially produce Willow's CBG at their European facilities. Since that time, Willow has tech-transferred its proprietary yeast strain and process to the CMO's facilities and run multiple pilot production batches to further optimize the process and provide additional samples of CBG to prospective customers. Our process continues to provide high-purity CBG with no detectable tetrahydrocannabinol (THC) or any other ca...